Skip to main content

View full-text article in PMC

. 2022 Mar 15;32(2):89–97. doi: 10.1089/cap.2021.0107

Table 4.

Patch Application-Site Treatment-Emergent Adverse Events (Safety Population)

	Dose-optimization period, n (%)	Double-blind period, n (%)
	d-ATS (all doses) (N = 110)	d-ATS (all doses) (N = 105^a)	Placebo (N = 105^b)
Pain	11 (10.0)	0 (0.0)	0 (0.0)
Pruritus	8 (7.3)	0 (0.0)	0 (0.0)
Burn	3 (2.7)	0 (0.0)	0 (0.0)
Erythema	2 (1.8)	1 (1.0)	0 (0.0)
Discomfort	1 (0.9)	0 (0.0)	0 (0.0)
Edema	1 (0.9)	0 (0.0)	0 (0.0)
Swelling	1 (0.9)	1 (1.0)	0 (0.0)

^{^a}

One patient discontinued the study before crossing over to d-ATS.

^{^b}

One patient was dispensed placebo patches for Visit 6 of the double-blind phase but did not return for any safety assessments.